PROVANTAGE HEALTH SERVICES INC
SC 14D9/A, EX-99.A6, 2000-06-06
SPECIALTY OUTPATIENT FACILITIES, NEC
Previous: PROVANTAGE HEALTH SERVICES INC, SC 14D9/A, 2000-06-06
Next: MAKE IT HAPPEN MANAGEMENT, 8-K, 2000-06-06





                                   LETTERHEAD
                                       OF
                    MILBERG WEISS BERSHAD HYNES & LERACH LLP



                                  May 31, 2000



Via Facsimile

Board of Directors of Shopko
Board of Directors of ProVantage
c/o Nancy Senate
FOLEY & LARDNER
150 East Gilman Street
Madison, WI  53701-1497

Board of Directors of Merck
c/o Gary P. Cooperstein
FRIED, FRANK, HARRIS, SHRIVER & JACOBSON
One New York Plaza
New York, NY  10004

     Re:  ProVantage Shareholder Litigation

Dear Board Members:

     The  Tender  Offer  Documents   issued  in  connection  with  the  sale  of
ProVantage, Inc., including the SEC forms 14D-1 and 14-9 ("Documents") are false
and misleading in that they fail to disclose material information rendering such
documents false and misleading.

     The Documents conceal material  information relating to the motivations and
benefits  which will be obtained by the Board Members of  ProVantage  and Shopko
upon  consummation  of the  transaction.  For  example,  the  Documents  fail to
disclose the fact that Shopko's 61%  ownership  interest in ProVantage is highly
illiquid.  Though Shopko's ownership stake was no longer subject to the Rule 144
time restrictions,  it was subject to the Rule 144 volume restrictions which, as
a practical  matter,  effectively  precluded  it from  selling  its  interest in
ProVantage  for years at anywhere near the price  obtained in this  transaction.
Unlike Shopko,  our client and the other public  stockholders of ProVantage were
not so  disadvantaged  as they have never faced the illiquidity  issues faced by
Shopko.



<PAGE>


FOLEY & LARDNER
Board of Directors of Shopko
May 31, 2000
Page 2



     The  Documents  also  conceal the  benefits  that will be reaped by Girard,
Kramer, Wolf and Podany upon consummation of the Tender Offer by virtue of their
relationship with Shopko. Furthermore,  the Documents conveniently omit from the
"Background" section that on February 29, 2000, one day after Merck submitted an
offer to purchase the company,  ProVantage granted options to key officers which
have a post-exercise price value of $1,450,000.

     The Documents are fraught with material omissions and misstatements.  Merck
must refrain from purchasing ProVantage shares from ProVantage's shareholders in
the Tender Offer until it makes adequate disclosure of all material  information
to ProVantage shareholders. Plaintiffs' concerns with the Tender Offer documents
are many and  given the  defects  in these  materials,  our  client  immediately
attempted to contact Nancy Senate, Shopko's and ProVantage's counsel, to apprise
her of the  necessity  of  correcting  these  problems  and/or  refraining  from
consummating the Tender Offer, as proposed. She has not responded. We view these
issues as extremely important.

     The Tender Offer is scheduled to close on June 14, 2000.  Accordingly,  the
necessary  corrections must be provided to ProVantage  shareholders on or before
June 5, 2000. If we do not hear from you on or before Thursday, June 1, 2000, we
will  arrange  to take  the  necessary  steps  to  protect  ProVantage's  public
stockholders.

                                               Very truly yours,

                                               /s/ Randall H. Steinmeyer

                                               RANDALL H. STEINMEYER



© 2022 IncJournal is not affiliated with or endorsed by the U.S. Securities and Exchange Commission